Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Mehdi H. Hamadani MD

Mehdi H. Hamadani MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


Publications

  • Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review From the Late Effects and Quality of Life Working Committee of the CIBMTR and Complications and Quality of Life Working Party of the EBMT. (Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE) Biol Blood Marrow Transplant 2017 Sep 19 PMID: 28939455 09/25/2017
  • Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. (Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB) Transfusion 2017 Aug 23 PMID: 28836275 08/25/2017
  • Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. (Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A) Hematol Oncol Stem Cell Ther 2017 Aug 16 PMID: 28830801 08/24/2017
  • Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN) Biol Blood Marrow Transplant 2017 Aug 07 PMID: 28797780 08/12/2017
  • Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. (Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M) Br J Haematol 2017 Aug 02 PMID: 28771676 08/05/2017
  • Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. (Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR) Biol Blood Marrow Transplant 2017 Jul 27 PMID: 28757436 08/02/2017
  • Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. (Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2017 Jul;17(7):408-414 PMID: 28756899 08/02/2017
  • Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. (Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P) Haematologica 2017 Oct;102(10):1767-1775 PMID: 28751562 PMCID: PMC5622861 07/29/2017
  • C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. (Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ) Cancer 2017 Jul 27 PMID: 28749548 07/28/2017
  • Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 07/13/2017
  • Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. (D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P) Leukemia 2017 Sep;31(9):1998-2000 PMID: 28663578 PMCID: PMC5587375 07/01/2017
  • Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. (Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M) J Clin Oncol 2017 Sep 10;35(26):3002-3009 PMID: 28644773 PMCID: PMC5590802 06/24/2017
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 06/21/2017
  • Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. (Epperla N, Hamadani M) Hematol Oncol Stem Cell Ther 2017 Jun 13 PMID: 28633038 06/21/2017
  • Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. (Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M) J Hematol Oncol 2017 Jun 12;10(1):117 PMID: 28606176 PMCID: PMC5469142 06/14/2017
  • PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 Jul 13;130(2):221-228 PMID: 28468799 PMCID: PMC5510790 05/05/2017
  • Incidence and survival trends in mantle cell lymphoma. (Epperla N, Hamadani M, Fenske TS, Costa LJ) Br J Haematol 2017 Apr 25 PMID: 28444739 04/27/2017
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 04/17/2017
  • Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. (Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P) Clin Lymphoma Myeloma Leuk 2017 Apr;17(4):201-206 PMID: 28395812 04/12/2017
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. (Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME) J Clin Oncol 2017 Apr 10;35(11):1154-1161 PMID: 28380315 PMCID: PMC5455603 04/06/2017
  • Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? (Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, Hamadani M) Bone Marrow Transplant 2017 Apr 03 PMID: 28368373 04/04/2017
  • Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. (Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P) Biol Blood Marrow Transplant 2017 Jun;23(6):952-957 PMID: 28288949 03/16/2017
  • Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 May;17(5):305-311.e2 PMID: 28284742 03/13/2017
  • Treatment of severe mucositis pain with oral ketamine mouthwash. (Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A) Support Care Cancer 2017 Jul;25(7):2215-2219 PMID: 28190158 PMCID: PMC5500907 02/13/2017
  • Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? (Jethava Y, Guru Murthy GS, Hamadani M) Hematol Oncol Stem Cell Ther 2017 Jun;10(2):47-56 PMID: 28183681 02/12/2017
  • Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. (Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H) Biol Blood Marrow Transplant 2017 May;23(5):853-856 PMID: 28161608 PMCID: PMC5410937 02/06/2017
  • Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. (Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P) Clin Lymphoma Myeloma Leuk 2017 Mar;17(3):165-172 PMID: 28159578 02/06/2017
  • Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. (Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W) Biol Blood Marrow Transplant 2017 May;23(5):767-775 PMID: 28115276 PMCID: PMC5590102 01/25/2017
  • Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Jan 08 PMID: 28066928 01/10/2017
  • Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). (Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston A) Bone Marrow Transplant 2017 Feb;52(2):321-322 PMID: 27892948 11/29/2016
  • Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. (Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M) Am J Hematol 2017 Feb;92(2):161-170 PMID: 27880984 PMCID: PMC5549936 11/24/2016
  • Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. (Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Feb;23(2):269-277 PMID: 27864161 PMCID: PMC5346183 11/20/2016
  • Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. (Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Jan;23(1):60-66 PMID: 27789362 PMCID: PMC5182098 10/30/2016
  • Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN) Biol Blood Marrow Transplant 2016 Dec;22(12):2117-2125 PMID: 27660167 PMCID: PMC5116249 10/18/2016
  • Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. (Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E) Best Pract Res Clin Haematol 2016 Mar;29(1):54-66 PMID: 27742072 10/16/2016
  • Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. (Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2016 Dec;16(12):672-678 PMID: 27660080 09/24/2016
  • Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. (Epperla N, Olteanu H, Hamadani M) Br J Haematol 2016 Dec;175(5):758 PMID: 27650173 09/22/2016
  • Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. (Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M) Bone Marrow Transplant 2016 Dec;51(12):1602-1604 PMID: 27595288 09/07/2016
  • Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. (DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, Shaw BE) Bone Marrow Transplant 2017 Feb;52(2):173-182 PMID: 27548466 PMCID: PMC5288134 08/23/2016
  • Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. (Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M) Bone Marrow Transplant 2017 Jan;52(1):147-150 PMID: 27479688 08/02/2016
  • Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. (Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A) Future Oncol 2016 Nov;12(22):2631-2642 PMID: 27381652 07/07/2016
  • Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. (Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M) Biol Blood Marrow Transplant 2016 Oct;22(10):1773-1780 PMID: 27345140 06/28/2016
  • Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. (Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W) Cancer 2016 Oct;122(19):3005-3014 PMID: 27315441 PMCID: PMC5030151 06/18/2016
  • Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. (Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M) J Clin Oncol 2016 Sep 10;34(26):3141-9 PMID: 27269951 PMCID: PMC5012706 06/09/2016
  • Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. (DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers MED, Savani BN, Shaw BE, CIBMTR Late Effects and Quality of Life Working Committee, EBMT Complications and Quality of Life Working Party) Biol Blood Marrow Transplant 2016 Aug;22(8):1493-1503 PMID: 27184625 PMCID: PMC4949101 05/18/2016
  • Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 05/11/2016
  • Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. (Snyder M, Shillingburg A, Newton M, Hamadani M, Kanate AS, Craig M, Cumpston A) Support Care Cancer 2016 Oct;24(10):4237-40 PMID: 27137211 05/04/2016
  • Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. (Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C) Biol Blood Marrow Transplant 2016 Sep;22(9):1543-1551 PMID: 27131863 PMCID: PMC4981559 05/02/2016
  • Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. (Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M) Br J Haematol 2016 Jul;174(2):235-48 PMID: 26989808 PMCID: PMC4940282 03/19/2016
  • Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. (Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA) Immunotherapy 2016;8(4):435-47 PMID: 26973125 03/15/2016
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. (Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W) Biol Blood Marrow Transplant 2016 Jun;22(6):1056-1064 PMID: 26964698 PMCID: PMC4877686 03/12/2016
  • Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. (Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, Hamadani M, Petros W) Antimicrob Agents Chemother 2016 Jan 11;60(3):1830-3 PMID: 26824940 PMCID: PMC4775958 01/30/2016
  • Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. (El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, Kharfan-Dabaja MA) Biol Blood Marrow Transplant 2016 May;22(5):802-14 PMID: 26713431 12/30/2015
  • Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. (Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ, Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium) Am J Hematol 2016 Mar;91(3):322-9 PMID: 26701142 PMCID: PMC4764423 12/25/2015
  • Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. (Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M) Blood 2016 Feb 18;127(7):938-47 PMID: 26670632 PMCID: PMC4760094 12/17/2015
  • Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. (Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS) Cytotherapy 2015 Dec;17(12):1785-92 PMID: 26475754 PMCID: PMC4700501 10/18/2015
  • Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. (Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B) Bone Marrow Transplant 2016 Feb;51(2):300-2 PMID: 26457913 10/13/2015
  • Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. (Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M) Bone Marrow Transplant 2016 Jan;51(1):58-66 PMID: 26437062 PMCID: PMC4703480 10/06/2015
  • Ibrutinib in Refractory Classic Hodgkin's Lymphoma. (Hamadani M, Balasubramanian S, Hari PN) N Engl J Med 2015 Oct;373(14):1381-2 PMID: 26422743 10/01/2015
  • Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. (Epperla N, Fenske TS, Hari PN, Hamadani M) World J Transplant 2015 Sep 24;5(3):81-8 PMID: 26421260 PMCID: PMC4580930 10/01/2015
  • Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. (Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M) J Oncol Pharm Pract 2016 Oct;22(5):666-78 PMID: 26320127 09/01/2015
  • Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. (Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A) Bone Marrow Transplant 2015 Dec;50(12):1513-8 PMID: 26301967 PMCID: PMC4548821 08/25/2015
  • Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. (Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A) Am J Hematol 2015 Nov;90(11):E212-3 PMID: 26284951 PMCID: PMC4618044 08/19/2015
  • Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? (Epperla N, Fenske TS, Lazarus HM, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1393-404 PMID: 26281033 08/19/2015
  • Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099 PMID: 26253007 PMCID: PMC4639453 08/09/2015
  • A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. (Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1416-23 PMID: 26237164 PMCID: PMC4633349 08/04/2015
  • Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. (Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M, Center for International Blood and Marrow Transplant Research Lymphoma Working Committee) Biol Blood Marrow Transplant 2015 Sep;21(9):1605-11 PMID: 25983043 PMCID: PMC4558181 05/20/2015
  • Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. (Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS) Antimicrob Agents Chemother 2015 Aug;59(8):4424-8 PMID: 25987632 PMCID: PMC4505228 05/20/2015
  • The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. (Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W) Biol Blood Marrow Transplant 2015 Oct;21(10):1746-53 PMID: 25981509 PMCID: PMC4568162 05/20/2015
  • Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. (Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL) Bone Marrow Transplant 2015 Aug;50(8):1057-62 PMID: 25915806 PMCID: PMC4527880 04/29/2015
  • Secondary solid cancer screening following hematopoietic cell transplantation. (Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS) Bone Marrow Transplant 2015 Aug;50(8):1013-23 PMID: 25822223 PMCID: PMC4989866 03/31/2015
  • A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. (Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM) Clin Lymphoma Myeloma Leuk 2015 Jul;15(7):428-432.e2 PMID: 25776192 PMCID: PMC4484305 03/18/2015
  • Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. (Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2015 Jul;21(7):1155-66 PMID: 25769794 03/15/2015
  • Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. (Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M) Bone Marrow Transplant 2015 Apr;50(4):610-2 PMID: 25621807 01/27/2015
  • Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. (Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2015 Mar;21(3):552-8 PMID: 25528388 PMCID: PMC4329042 12/22/2014
  • Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG) Lancet Oncol 2014 Dec;15(13):1503-12 PMID: 25456369 12/03/2014
  • Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. (Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):199-207 PMID: 25445467 12/03/2014
  • Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. (Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN) Bone Marrow Transplant 2015 Mar;50(3):449-51 PMID: 25387097 11/12/2014
  • Autologous hematopoietic cell transplantation: an update for clinicians. (Hamadani M) Ann Med 2014 Dec;46(8):619-32 PMID: 25211470 09/12/2014
  • Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 PMID: 25111581 08/12/2014
  • Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. (Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK) Biol Blood Marrow Transplant 2014 Nov;20(11):1729-36 PMID: 25008330 PMCID: PMC4194275 07/11/2014
  • Reply to S. Fuji et al. (Hamadani M, Vos JA, Craig MD) J Clin Oncol 2014 Jun 10;32(17):1860-1 PMID: 24799471 05/07/2014
  • Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 05/03/2014
  • Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. (Kanate AS, Pasquini MC, Hari PN, Hamadani M) World J Stem Cells 2014 Apr 26;6(2):69-81 PMID: 24772235 PMCID: PMC3999783 04/29/2014
  • Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. (Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W) Biol Blood Marrow Transplant 2014 Jul;20(7):951-9 PMID: 24641828 PMCID: PMC4060436 03/20/2014
  • Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. (McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ) Biol Blood Marrow Transplant 2014 Jul;20(7):960-8 PMID: 24641829 PMCID: PMC4057955 03/20/2014
  • Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. (Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA) Semin Hematol 2014 Jan;51(1):73-86 PMID: 24468319 01/29/2014
  • Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. (Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I) Biol Blood Marrow Transplant 2014 May;20(5):646-54 PMID: 24462982 01/28/2014
  • Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! (Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN) Bone Marrow Transplant 2014 May;49(5):599-606 PMID: 24442246 01/21/2014
  • Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter? (Hamadani M) Biol Blood Marrow Transplant 2014 Mar;20(3):292-4 PMID: 24394802 01/08/2014
  • Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. (Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS) Biol Blood Marrow Transplant 2014 Mar;20(3):415-20 PMID: 24361913 PMCID: PMC4557764 12/24/2013
  • Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. (Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN) J Clin Oncol 2014 Feb 01;32(4):273-81 PMID: 24344210 PMCID: PMC3897255 12/18/2013
  • Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. (Hamadani M, Gibson LF, Remick SC, Wen S, Petros W, Tse W, Brundage KM, Vos JA, Cumpston A, Bunner P, Craig MD) J Clin Oncol 2013 Dec 10;31(35):4416-23 PMID: 24166529 PMCID: PMC3842909 10/30/2013
  • Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. (Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2014 Jan;20(1):89-97 PMID: 24161923 PMCID: PMC3886623 10/29/2013
  • Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. (Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M) Clin Lymphoma Myeloma Leuk 2014 Feb;14(1):50-5 PMID: 24119465 10/15/2013
  • Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. (Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston A) Ann Hematol 2014 Apr;93(4):677-82 PMID: 24097085 10/08/2013
  • Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas. (Hamadani M, Kanate AS) Community Oncology Hamadani M., Kanate AS.: “Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas.” Community Oncology. 2013 October;10(10):279-281 10/01/2013
  • Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. (Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W) Blood 2013 Dec 05;122(24):3863-70 PMID: 24065243 PMCID: PMC3854108 09/26/2013
  • Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. (Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A) Br J Haematol 2013 Nov;163(3):315-25 PMID: 24033280 09/17/2013
  • Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. (Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M) J Clin Apher 2013 Oct;28(5):359-67 PMID: 23765597 06/15/2013
  • Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. (Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M) Bone Marrow Res 2013;2013:414959 PMID: 23691325 PMCID: PMC3652129 05/22/2013
  • Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes. (Kanate AS, Watkins K, Cumpston A, Craig M, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1133-5 PMID: 23635452 05/03/2013
  • Management strategies for follicular lymphoma patients in remission after modern frontline chemoimmunotherapies. (Chaudhary L, Hamadani M) Journal of Blood Disorders & Transfusion Chaudhary L, Hamadani M (2012) Management Strategies for Follicular Lymphoma patients in Remission after Modern Frontline Chemoimmunotherapies. J Blood Disorders Transf 3:e105 05/01/2013
  • Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. (Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M) Biol Blood Marrow Transplant 2013 Sep;19(9):1288-300 PMID: 23618718 04/27/2013
  • Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? (Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M) Bone Marrow Transplant 2013 Nov;48(12):1489-96 PMID: 23584438 04/16/2013
  • Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. (Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M) Bone Marrow Transplant 2013 Oct;48(10):1279-84 PMID: 23584435 04/16/2013
  • Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. (Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1006-12 PMID: 23396213 02/12/2013
  • Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM) Biol Blood Marrow Transplant 2013 May;19(5):746-53 PMID: 23380340 PMCID: PMC3650915 02/06/2013
  • Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM) Biol Blood Marrow Transplant 2013 Apr;19(4):625-31 PMID: 23333532 PMCID: PMC3640440 01/22/2013
  • Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. (Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A) J Hematol Oncol 2013 Jan 04;6:2 PMID: 23289975 PMCID: PMC3548722 01/08/2013
  • Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit. (Cumpston A, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR) Transpl Infect Dis 2013 Apr;15(2):142-9 PMID: 23279656 01/03/2013
  • Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. (Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL) Biol Blood Marrow Transplant 2013 Feb;19(2):173-9 PMID: 23200705 PMCID: PMC3553321 12/04/2012
  • Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. (Kanate AS, Kharfan-Dabaja MA, Hamadani M) Bone Marrow Res 2012;2012:897215 PMID: 23097707 PMCID: PMC3477524 10/26/2012
  • Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. (Ross AL, Slain D, Cumpston A, Bryant AM, Hamadani M, Craig M) Int J Antimicrob Agents 2012 Dec;40(6):557-61 PMID: 23068599 10/17/2012
  • Rituximab maintenance versus retreatment in follicular lymphoma. (Palla AR, Hamadani M) Hematol Oncol 2013 Dec;31(4):171-8 PMID: 23044794 10/10/2012
  • Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? (Hamadani M) Bone Marrow Transplant 2013 Aug;48(8):1013-21 PMID: 23000653 09/25/2012
  • Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit. (Sweet MA, Cumpston A, Briggs F, Craig M, Hamadani M) Am J Infect Control 2012 Dec;40(10):931-4 PMID: 22575286 05/12/2012
  • Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. (Awan FT, Kochuparambil ST, Deremer D, Cumpston A, Craig M, Jillella A, Hamadani M) J Oncol 2012;2012:931071 PMID: 22570654 PMCID: PMC3335320 05/10/2012
  • Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. (Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W) Biol Blood Marrow Transplant 2012 Sep;18(9):1446-54 PMID: 22449610 PMCID: PMC3499973 03/28/2012
  • Regulation of acute graft-versus-host disease by microRNA-155. (Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R) Blood 2012 May 17;119(20):4786-97 PMID: 22408260 PMCID: PMC3367879 03/13/2012
  • Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. (Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F) Biol Blood Marrow Transplant 2012 Jul;18(7):1128-35 PMID: 22248715 01/18/2012
  • Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. (Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, Hamadani M) Hematol Oncol Stem Cell Ther 2011;4(4):149-56 PMID: 22198185 12/27/2011
  • Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Mohty M, Kharfan-Dabaja MA) Cancer Control 2011 Oct;18(4):237-45 PMID: 21976242 10/07/2011
  • CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells. (Liu K, Anthony BA, Yearsly MM, Hamadani M, Gaughan A, Wang JJ, Devine SM, Hadley GA) PLoS One 2011;6(7):e21968 PMID: 21779359 PMCID: PMC3136479 07/23/2011
  • Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. (Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN) Blood 2011 Aug 18;118(7):1979-88 PMID: 21690560 PMCID: PMC3158724 06/22/2011
  • Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. (Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M) Bone Marrow Transplant 2012 Jan;47(1):146-8 PMID: 21358681 03/02/2011
  • Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. (Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM) Hematol Oncol 2011 Dec;29(4):202-10 PMID: 21360728 PMCID: PMC3557914 03/02/2011
  • The evolving role of statins in hematopoietic stem and progenitor cell transplantation. (Hamadani M, Craig MD, Gibson LF, Remick SC) Am J Blood Res 2011;1(1):57-64 PMID: 22432066 PMCID: PMC3301410 01/01/2011
  • Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. (Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA) J Clin Oncol 2010 Nov 01;28(31):e629-32 PMID: 20733121 08/25/2010
  • How we approach patient evaluation for hematopoietic stem cell transplantation. (Hamadani M, Craig M, Awan FT, Devine SM) Bone Marrow Transplant 2010 Aug;45(8):1259-68 PMID: 20479713 05/19/2010
  • Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis. (Hamadani M, Awan F, Villalona-Calero MA) Am J Clin Oncol 2010 Feb;33(1):109 PMID: 20139744 02/09/2010
  • Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. (Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM) Leuk Lymphoma 2010 Feb;51(2):243-51 PMID: 20038230 PMCID: PMC3557809 12/30/2009
  • Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. (Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM) Biol Blood Marrow Transplant 2009 Nov;15(11):1422-30 PMID: 19822302 PMCID: PMC3953136 10/14/2009
  • Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. (Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA) Br J Haematol 2010 Feb;148(4):623-6 PMID: 19821825 10/14/2009
  • Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. (Hamadani M, Devine SM) Blood 2009 Sep 17;114(12):2564-6 PMID: 19762505 09/19/2009
  • Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. (Hamadani M, Awan FT) Hematol Oncol 2010 Mar;28(1):3-12 PMID: 19645073 08/01/2009
  • Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. (Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM) Biol Blood Marrow Transplant 2009 May;15(5):547-53 PMID: 19361746 PMCID: PMC3953134 04/14/2009
  • Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. (Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC) Leuk Lymphoma 2009 Mar;50(3):349-56 PMID: 19263294 PMCID: PMC3695225 03/06/2009
  • Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Blum W) Clinical Leukemia Hamadani M., Blum W.: “Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia.” Clinical Leukemia. 2009 February;3(1):47-57 02/01/2009
  • Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM) Leuk Lymphoma 2008 Oct;49(10):1893-8 PMID: 18949613 10/25/2008
  • Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? (Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzoni M) J Clin Oncol 2008 Nov 01;26(31):5134-6; author reply 5136-7 PMID: 18838697 10/08/2008
  • High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM) Eur J Haematol 2008 Dec;81(6):425-31 PMID: 18774954 09/09/2008
  • Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. (Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM) Biol Blood Marrow Transplant 2008 Jul;14(7):783-9 PMID: 18541197 PMCID: PMC4100722 06/11/2008
  • Review: isolated skeletal involvement in hairy cell leukemia. (Hamadani M, Kraut EH) Clin Adv Hematol Oncol 2008 Apr;6(4):294-6 PMID: 18496496 05/23/2008
  • Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Awan FT, Copelan EA) Biol Blood Marrow Transplant 2008 May;14(5):556-67 PMID: 18410898 04/16/2008
  • The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. (Hamadani M, Awan FT, Devine SM) Blood 2008 Apr 01;111(7):3901-2 PMID: 18362217 03/26/2008
  • Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM) Biol Blood Marrow Transplant 2008 Apr;14(4):480-3 PMID: 18342792 03/18/2008
  • The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. (Hamadani M, Hade E, Benson DM Jr, Hofmeister CC) Biol Blood Marrow Transplant 2008 Mar;14(3):351-2 PMID: 18275902 02/16/2008
  • False-negative PET scan with bronchioloalveolar carcinoma: an important diagnostic caveat. (Awab A, Hamadani M, Peyton M, Brown B) Am J Med Sci 2007 Oct;334(4):311-3 PMID: 18030191 11/22/2007
  • An unusual etiology of chest pain. (Rashid A, Afaq A, Hamadani M, Warraich J, Hennebry T) J Okla State Med Assoc 2007 Sep;100(9):352-3 PMID: 18020040 11/21/2007
  • CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). (Hamadani M, Magro CM, Porcu P) Br J Haematol 2008 Jan;140(2):122 PMID: 17991297 11/10/2007
  • Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? (Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A) J Oncol Pharm Pract 2007 Jun;13(2):69-75 PMID: 17873106 09/18/2007
  • Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. (Vrindavanam N, Hamadani M, Steele B, Awan F, Suster S, Benson DM Jr) Am J Hematol 2007 Dec;82(12):1120-1 PMID: 17654679 07/27/2007
  • Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. (Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM) Transpl Infect Dis 2008 Feb;10(1):24-6 PMID: 17651365 07/27/2007
  • Gastrointestinal chronic graft-versus-host disease: management options. (Awan F, Hamadani M) J Oncol Pharm Pract 2007 Mar;13(1):49-51 PMID: 17621568 07/11/2007
  • Thalidomide-induced fulminant hepatic failure. (Hamadani M, Benson DM Jr, Copelan EA) Mayo Clin Proc 2007 May;82(5):638 PMID: 17493431 05/12/2007
  • Paraneoplastic Sweet's syndrome and the pathergy phenomenon. (Awan F, Hamadani M, Devine S) Ann Hematol 2007 Aug;86(8):613-4 PMID: 17468870 05/01/2007
  • Gastroparesis. (Ali T, Hasan M, Hamadani M, Harty RF) South Med J 2007 Mar;100(3):281-6 PMID: 17396732 04/03/2007
  • Limitations of Sokal score in patients with chronic myeloid leukemia. (Hamadani SM, Chaudhary L) J Coll Physicians Surg Pak 2007 Mar;17(3):182; author reply 182 PMID: 17374310 03/22/2007
  • Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. (Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC) Bone Marrow Transplant 2007 Feb;39(4):249-51 PMID: 17290281 02/10/2007
  • McCune-Albright syndrome. (Hamadani M, Chaudhary L) Med J Aust 2006 Dec 4-18;185(11-12):597 PMID: 17181499 12/22/2006
  • Role of thiamine in managing ifosfamide-induced encephalopathy. (Hamadani M, Awan F) J Oncol Pharm Pract 2006 Dec;12(4):237-9 PMID: 17156595 12/13/2006
  • Early detection of digitalis-induced nonocclusive mesenteric ischemia using Doppler ultrasonography. (Awab A, Hamadani M, Saya S, Whitsett T) South Med J 2006 Oct;99(10):1142 PMID: 17100040 11/15/2006
  • Infected atrial myxoma. (Awab A, Hamadani M, Sud B, Voskuhl GW) Med J Aust 2006 Sep 18;185(6):332 PMID: 16999677 09/27/2006
  • Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy. (Hamadani M, Awab A, Chaudhary L, Tfayli A) J Oncol Pharm Pract 2006 Jun;12(2):67-8 PMID: 16984743 09/21/2006
  • Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. (Tfayli A, Selby G, Maqbool F, Bierbaum W, Hamadani M) Am J Hematol 2006 Dec;81(12):959-62 PMID: 16924649 08/23/2006
  • Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome. (Hamadani M, Awab A, Rashid A, Ali T, Brown B) J Coll Physicians Surg Pak 2006 May;16(5):376-7 PMID: 16756788 06/08/2006
  • Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. (Hamadani M, Kharfan-Dabaja M, Kamble R, Kern W, Ozer H) J Okla State Med Assoc 2006 Apr;99(4):154-6 PMID: 16703935 05/18/2006
  • Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. (Kamble RT, Hamadani M, Selby GB) J Antimicrob Chemother 2006 Apr;57(4):795-6 PMID: 16476723 02/16/2006
  • Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance. (Kamble RT, Hamadani M, Selby GB) Biol Blood Marrow Transplant 2006 Jan;12(1):111-2 PMID: 16399575 01/10/2006
  • Granulocytic sarcoma manifesting as multiple skeletal lesions. (Hamadani M, Tfayli A, Sethi S, Awab A, Hamdani N) Am J Med Sci 2005 Sep;330(3):139-43 PMID: 16174998 09/22/2005
  • Last update: 10/11/2017
    jenkins-FCD Prod-141 f776ee82366dc5656a368d51cce32734d2f9b9a0